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BACKGROUND/OBJECTIVES: Enteral nutrition formulas with immune-enhancing nutrients, such as n-3 fatty acids, may manage 
patients’ nutritional status and pathophysiological processes. The aim of our study was to investigate natural killer (NK) cell 
activity alterations and related cytokine changes resulting from feeding with soybean oil-containing enteral nutrition formula 
(control group) and plant-derived n-3 fatty acid-enriched enteral nutrition formula. 
SUBJECTS/METHODS: Subjects participated for 14 consecutive days and consumed enteral formula containing canola and flaxseed 
oil (n3EN, test group) in nonsurgical patients hospitalized for rehabilitation. Blood samples were collected on the first day 
and 14 days after the consumption of each formula daily, and anthropometric parameters were collected. Hematology and 
biochemical values were analyzed, and NK cell activities and serum cytokine concentration were measured. A total of sixty 
subjects were included in the analysis, excluding dropouts. 
RESULTS: No significant differences were found in biochemical parameters. The n3EN group’s NK cell activities at effector:tumor 
cell ratios of 10:1, 5:1, 2.5:1 and 0.625:1 were significantly higher than those of the control group after two weeks (P < 0.05). 
However, there were no statistically significant differences in serum cytokine interleukin (IL)-12, interferon-γ, IL-1β, IL-6 and 
tumor necrosis factor-α values between the two groups. 
CONCLUSIONS: In conclusion, this study elucidates the beneficial effects of plant-derived n-3 fatty acid supplementation in 
enteral formula on NK cell activity.
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INTRODUCTION3)
Enteral nutrition is preferred over parenteral nutrition for 
hospitalized patients who are unable to meet their nutritional 
requirements with an oral diet [1,2]. Immune-enhancing enteral 
nutrition formulas containing n-3 fatty acids, selenium, and 
antioxidants may manage patients’ nutritional status and 
pathophysiological processes [3,4]. The fat sources traditionally 
used in enteral nutrition are based on n-6 fatty acid-rich oils, 
such as soybean oil; however, such sources may not be ideal 
because they may provide excess linoleic acid [5], which is a 
precursor for pro-inflammatory arachidonic acid synthesis [6]. 
Clinical trials regarding the immunomodulatory effect of n-3 
fatty acids have been reported in previous studies [7,8]. Meta- 
analyses of controlled, randomized clinical trials using n-3 fatty 
acids or similar formulas to enhance immune functions have 
shown marked decreases in the length of hospital stay and 
infection events; however, these effects are more significant in 
critically ill [9-11] or postoperative patients [12].
Immune-enhancing enteral formulas, also known as immune- 
enhancing formulas, typically include arginine, glutamine, 
nucleic acids, and n-3 fatty acids [13]. The aim of these formulas 
is to reduce complications associated with infection and protect 
and stimulate the immune system [11,14-16]. Perioperative 
immunomodulating enteral nutrition has been recommended 
for surgical patients by the European Society for Clinical 
Nutrition and Metabolism (ESPEN) guidelines [17]. Although 
many immune-enhancing enteral nutrition guidelines strive to 
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Fig. 1. Flow diagram of randomized participants
achieve better patient care outcomes, a precise definition of 
the desirable properties of immune-strengthening fatty acid 
components in enteral nutrition formulas for chronic nonsurgical 
hospitalized inpatients is still lacking.
Natural killer (NK) cells regulate immune and inflammatory 
reactions by presenting multiple cytokines, particularly interferon 
(IFN)-γ, a potent immune-activating cytokine [11]. NK cell 
activity and cytokines can serve as parameters of a patient’s 
immune status. Moreover, rehabilitation inpatients are vulnerable 
to infectious complications because of their prolonged hospital 
stays [18]. Although no clear evidence regarding the immune- 
enhancing effect of n-3 fatty acids derived from plants on NK 
cell activity is available, plant-derived n-3 fatty acids can be 
effective for regulating the immune system [19,20] because they 
are rich in α-linolenic acid. However, few studies have compared 
the effect of enteral formulas enriched with plant-derived n-3 
fatty acids in nonsurgical rehabilitation patients with that of 
a soybean oil formula as a control. 
Malnutrition is commonly encountered in long-term hospi-
talized patients, such as rehabilitation patients, and these 
patients require specific nutritional strategies [21]. Therefore, 
the goal of our research was to compare NK cell activity 
alterations and related cytokine changes associated with a 
soybean oil formula (control) and a plant-derived n-3 fatty 
acid-enriched formula (test) in nonsurgical patients hospitalized 
for rehabilitation. 
SUBJECTS AND METHODS
Participants
From August 2015 to March 2018, ninety-four patients were 
enrolled in this study after admission to the department of 
rehabilitation at Yonsei University Severance Hospital (Seoul, 
Republic of Korea). The eligibility criteria included adult male 
and female patients aged 19 years and older who received 
enteral nutrition through tube feeding. The exclusion criteria 
were hepatic impairment, renal impairment, or diabetic 
problems, active chemotherapy, a life expectancy of less than 
1 month, pregnancy, and the presence of other acute diseases 
that could affect a patient's pathophysiological condition. 
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Soybean oil formula
(control group)
n-3 fatty acid-enriched 
formula
(n3EN, test group)
Fat ingredients/source
(percentage ratio)
Soybean, medium chain 
triglycerides (MCT)
(55:45)
Canola, flaxseed, MCT
(44.4:11.1:44.5)
Calories (kcal) 200 200
Total fat (g) 4.5 6.0
Saturated fat (g) 2.0 2.4
Trans fat (g) 0.0 0.0
Total carbohydrate (g) 34.0 30.0
Protein (g) 8.0 8.0
Fiber (g) 3.0 2.5
Cholesterol (mg) 0.00 0.00
Vitamin A (μgRE) 150.00 150.00
Vitamin B1 (mg) 0.24 0.24
Vitamin B2 (mg) 0.30 0.30
Vitamin B6 (mg) 0.30 0.30
Vitamin B12 (μg) 0.48 0.48
Vitamin C (mg) 20.00 20.00
Vitamin D (μg) 1.00 2.00
Vitamin E (mgα-TE) 2.00 2.00
Vitamin K (μg) 15.00 15.00
Niacin (mg NE) 3.20 3.20
Folic acid (μg) 80.00 80.00
Pantothenic acid (mg) 1.00 1.00
Biotin (μg) 6.00 6.00
Calcium (mg) 140.00 140.00
Phosphorus (mg) 140.00 140.00
Potassium (mg) 200.00 260.00
Magnesium (mg) 44.00 44.00
Iron (mg) 2.00 2.00
Zinc (mg) 2.00 2.00
Sodium (mg) 120.00 120.00
Copper (mg) 0.10 0.16
Manganese (mg) 0.46 0.70
Table 1. Composition of the enteral nutrition product of the control and test
groups
However, thirty- four subjects discontinued the study for 
personal reasons, including a change to another formula or 
withdrawal, inter/ intrahospital transfer, or nil per os for the 
treatment of other diseases. None of the withdrawals were due 
to serious adverse effects. The results of this study are based 
on an analysis of sixty subjects after excluding the dropouts. 
In total, forty-three quadriplegic patients, five patients with 
hemiplegia of a cerebellar pathophysiological origin, eleven 
patients with ataxic quadriparesis, and one patient with lateral 
medullary syndrome trauma were enrolled. No differences were 
identified between the test and control groups regarding the 
diagnostic distribution (P = 0.100, chi-square test). Informed 
consent was provided by the patients or a close family member. 
This research was approved by the Institutional Review Board 
of Yonsei University Severance Hospital, Seoul, Korea 
(Identification Approval number: 2015-0907). All compliance 
measures and medical histories of the study subjects were 
tracked under the IRB tracking number (ClinicalTrials.gov: 
NCT03638661; http://www.clinicaltrials.gov). 
Implementation of the randomized clinical trial
The principal indication for enteral nutrition is a patient with 
an intact and functional gastrointestinal tract but an impaired 
ability to swallow and/or difficulty with oral intake [22]. Because 
of severe metabolic changes and unstable vital signs, critically 
ill or postoperative patients are not suitable for enteral nutrition 
for more than 2 weeks and were therefore ineligible for this 
clinical trial. Additionally, an appropriate intestinal approach 
cannot be carried out in pre-/peri-/postoperative patients, and 
these subjects may have several contraindications to enteral 
nutrition. Therefore, we decided that rehabilitation patients 
were suitable for the current clinical study using standard 
nutrients with an n-3 fatty acid formula.
The first patient was enrolled in August 2015, and the last 
(94th) patient’s 2-week follow-up ended in March 2018. A flow 
diagram of the randomization of the subjects is presented in 
Fig. 1. The present study was designed as a parallel, randomized, 
human clinical trial. Using computer-generated simple sampling 
randomization lists (the SAS randomization program), ninety- 
four patients were randomized to receive either a soybean 
oil-containing enteral nutrition formula (control) or an n-3 fatty 
acid-enriched enteral nutrition formula containing canola and 
flaxseed oil (n3EN, test). Yonsei Dairy Co. generated the random 
allocation sequence and concealed the allocation table. The 
attending physicians of the Department of Rehabilitation at 
Yonsei University Severance Hospital enrolled the participants 
and allocated the subjects using the given sequence. The 
patients assigned to the control group received a soybean 
oil formula by tube feeding. Those assigned to the n3EN 
group received the n-3 fatty acid-enriched formula by tube 
feeding (product; Yonsei Dairy Co., Seoul, Republic of Korea). 
The ready-to-use soybean oil formula and n3EN formula had 
an identical appearance, with no dissimilarity in packing, 
texture, or smell. All of the participants, health care providers, 
outcome assessors and data analysts were blinded after 
assignment to the intervention groups. The concealed 
allocation tables were not uncovered before all the participants’ 
data had been clarified. 
Enteral nutrition formula intervention
The nutritional compositions of both the control and test 
enteral formulas are shown in Table 1. The nutrient (fatty acids) 
compositions of canola, flaxseed and soybean oils according 
to the United States Department of Agriculture database [23] are 
attached as supplemental data (Supplemental Table 1). The 
subjects participated for 14 consecutive days and consumed 
the enteral formula by either naso-gastric enteral tube feeding 
or a percutaneous endoscopic gastrostomy (PEG) enteral tube. 
Enteral nutrition was started within 24 h of hospital admission 
and supplied at a continuous rate to achieve a minimum of 
50% basal energy expenditure (BEE; determined using the 
Harris-Benedict equation) × 1.2 within the first 12 h. If well 
tolerated, enteral nutrition was increased to achieve BEE × 1.2 
within 48 h. Complementary delivery with parenteral nutrition 
was allowed for the initial 48 h. From the third day, the subjects 
received a minimum of 75% of BEE × 1.2. 
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Control group (n = 29) Test group (n = 31)
P-value1) P-value2)
Baseline Follow-up Baseline Follow-up
Age (yrs) 58.66 ± 2.90 57.26 ± 2.99 0.739
Male/female, n (%) 17 (58.6) / 12 (41.4) 21 (67.7) / 10 (32.3) 0.464
Weight (kg) 55.79 ± 1.71 56.33 ± 1.68 57.71 ± 1.81 57.20 ± 1.84 0.444 0.730
Body mass index (kg/m2) 20.27 ± 0.56 20.27 ± 0.58 21.17 ± 0.56 20.93 ± 0.53 0.262 0.410
Waist circumference (cm) 81.19 ± 2.11 82.45 ± 2.32 83.75 ± 1.40 83.02 ± 1.57 0.316 0.839
Calorie needs (kcal) 1,413.58 ± 34.27 1,380.44 ± 37.53 0.517
Average calorie intake (kcal) 1,367.97 ± 43.24 1,437.12 ± 46.57 0.282
Mean ± SE (standard error). 
1) P-values were derived from the chi-square test and independent t-test at baseline. 
2) P-values were derived from independent t-tests at the 2-week follow up
Table 2. Basic characteristics and anthropometric values in the control and test groups at baseline and at the 2-week follow up
Anthropometric parameters and blood collection
The subjects’ gender, age, height (cm), weight (kg), and 
weight change were tracked. Body weight during the hospital 
stay was derived from the medical records on the first and 14th 
days after consuming each formula and was used to calculate 
the body mass index (BMI = body weight (kg) / height (m2)) [24]. 
Venous blood samples were collected in EDTA-treated and plain 
tubes and centrifuged to acquire plasma and serum. The 
collected blood samples were preserved at -70°C until analysis.
Hematology and biochemical analysis
Serum glucose levels were measured according to the 
hexokinase method on a Hitachi 7600 autoanalyzer. Serum 
albumin concentrations were analyzed according to the BCG 
method with an ALB kit (Siemens, Tarrytown, NY, USA) using 
an ADVIA 2400 autoanalyzer (Siemens, Tarrytown, NY, USA). The 
leukocyte count was acquired using the HORIBA ABX diagnostic 
analyzer (HORIBA ABX SAS, ParcEuromedicine, Montpellier, 
France). Serum high-sensitivity C-reactive protein (hs-CRP) levels 
were determined with a kit from the N-Assay LA CRP-S D-TYPE 
(Nittobo, Tokyo, Japan) with a Hitachi 7600 autoanalyzer.
Natural killer (NK) cell activity
NK cell activity was the primary outcome measure of this 
study. Isolated PBMCs from the whole-blood specimens were 
incubated with K562 cells to measure the cytotoxicity of NK 
cells. The blood sample was mixed with the same amount of 
RPMI medium 1640 (Gibco, Thermo Fisher Scientific, Waltham, 
MA) and then carefully overlaid on Histopaque®1077 (Sigma- 
Aldrich, Irvine, UK) and centrifuged for 20 min at 1,800 rpm 
at 15°C. After separation, the buffer coat layer was isolated, 
washed once with RPMI 1640 medium, and then re-suspended 
in 1 mL of 10% fetal bovine serum. The isolated PBMCs (E, 
effector cells) were seeded onto 96-well plates at ratios of 10:1, 
5:1, 2.5:1, 1.25:1 and 0.625:1 with the K562 cells (T, target cell) 
and then incubated at 37°C under 5% CO2 for more than 4 h. 
The cytolytic activities of the NK cells were measured using the 
CytoTox 96® Non-Radioactive Cytotoxicity Assay Kit (Promega 
Co., Fitchburg, WI, USA) according to the manufacturer’s 
instructions. The optical density was read at 490 nm using a 
Victor × 5 2030 multi-label plate reader (PerkinElmer, Hopkinton, 
MA, USA), and the results were calculated by the following 
formula:
% Cytotoxicity = (Experimental-Effector Spontaneous-
Target Spontaneous)/
(Target Maximum-Target Spontaneous) × 100
Cytokine concentrations in serum
Serum cytokines were secondary outcome measures of this 
study. Interferon gamma (IFN-γ) was measured with an IFN-γ 
High-Sensitivity Human ELISA Kit (Abcam plc-Cambridge 
Science Park, Cambridge, UK) following to the manufacturer’s 
instructions. Interleukin (IL)-12 concentrations were analyzed 
with a High-Sensitivity Human IL-12 (P70) ELISA kit (Genway 
Biotech, Inc., San Diego, CA, USA) using a Victor × 5 2,030 
multi-label reader (PerkinElmer, Hopkinton, MA, USA) at 450 nm. 
IL-6, IL-1β, and tumor necrosis factor (TNF)-α concentrations in 
serum were measured using the Bio-Plex™ Reagent Kit (Bio-Rad 
Laboratories, Hercules, CA, USA).
Statistical analysis
Noncontinuous variables are presented as n values and 
percentages, whereas continuous variables are shown as the 
averages and the means ± standard errors (SE). All data were 
analyzed using SPSS version 24.0 (IBM/SPSS Corp., Chicago, IL, 
USA). Independent t-tests were used to compare parameters 
between the control and test (n3EN) groups. Chi-square tests 
were used to examine categorical values. For descriptive 
purposes, the mean values are presented using untransformed 
values. A two-tailed P-value less than 0.05 was considered 
statistically significant. 
RESULTS
Basic characteristics and anthropometric values
Table 2 outlines the basic characteristics at baseline and after 
two weeks for the control group and the n3EN group. At 
baseline, no significant differences were noted between the two 
groups in gender, age, weight, BMI, waist circumference, and 
the estimated average calorie intake (Table 2). After 2 weeks 
of consuming the enteral nutrition formulas, no statistically 
significant changes were observed in these clinical characteristics 
in the control and n3EN groups. Additionally, no noticeable 
differences were observed in the changes (differences from 
baseline) in these clinical characteristics between the two 
groups (Table 2).
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Control group (n = 29) Test group (n = 31)
P-value1) P-value2)
Baseline Follow-up Baseline Follow-up
White blood cells (× 103/μL) 7.51 ± 0.57 7.28 ± 0.41 6.33 ± 0.39 6.84 ± 0.51 0.095 0.499
Red blood cells (× 106/mm3) 4.03 ± 0.11 4.05 ± 0.08 3.98 ± 0.12 3.85 ± 0.11 0.748 0.131
Hemoglobin (g/dL) 12.01 ± 0.32 12.20 ± 0.26 12.13 ± 0.38 11.69 ± 0.32 0.808 0.220
Platelets (× 103/mm3) 269.71 ± 16.27 282.17 ± 15.97 261.68 ± 13.61 275.69 ± 13.19 0.706 0.756
Serum albumin (g/dL) 3.93 ± 0.07 3.99 ± 0.06 4.02 ± 0.08 3.94 ± 0.08 0.426 0.586
Prealbumin (mg/dL) 24.38 ± 1.15 28.86 ± 1.44 27.26 ± 1.47 26.61 ± 1.42 0.129 0.270
Transferrin (mg/dL) 223.55 ± 9.77 229.69 ± 8.50 242.94 ± 7.89 239.87 ± 8.41 0.128 0.398
Glucose (mg/dL) 104.83 ± 5.81 98.31 ± 3.86 97.36 ± 5.03 105.48 ± 5.11 0.335 0.268
HDL cholesterol (mg/dL) 42.21 ± 1.84 44.00 ± 2.11 41.71 ± 2.26 46.03 ± 2.40 0.865 0.527
LDL cholesterol (mg/dL) 96.34 ± 5.98 108.34 ± 5.96 83.63 ± 5.78 89.28 ± 7.57 0.131 0.053
GOT (IU/L) 29.90 ± 3.92 29.55 ± 3.46 25.58 ± 2.05 27.10 ± 2.32 0.335 0.558
GPT (IU/L) 25.10 ± 3.01 30.34 ± 4.21 23.16 ± 2.09 26.39 ± 4.23 0.599 0.510
hs-CRP (mg/L) 12.77 ± 3.86 9.78 ± 2.52 7.05 ± 1.37 9.30 ± 2.56 0.171 0.894
Free fatty acids (uEq/L) 344.96 ± 25.69 380.55 ± 42.51 315.19 ± 29.93 372.19 ± 48.50 0.454 0.898
Mean ± SE. 
1) P-values were derived from independent t-tests at baseline. 
2) P-values were derived from independent t-tests at the 2-week follow up. 
Table 3. Biochemical parameters of the control and test groups at baseline and at the 2-week follow up
Control group (n = 29) Test group (n = 31)
P-value1) P-value2) P-value3)
Baseline Follow-up Baseline Follow-up
NK cell activity E:T = 10:1 (%) 22.30 ± 2.94 16.74 ± 3.41** 19.33 ± 2.19 34.87 ± 5.06** 0.423 0.005
Change -4.94 ± 4.28 14.86 ± 5.09 0.005
NK cell activity E:T = 5:1 (%) 17.78 ± 2.27 15.02 ± 3.22* 15.11 ± 1.96 26.40 ± 3.49* 0.377 0.020
Change -3.01 ± 3.53 11.07 ± 3.85 0.009
NK cell activity E:T = 2.5:1 (%) 14.85 ± 2.03 12.80 ± 3.13* 13.46 ± 1.48 22.65 ± 3.56* 0.582 0.043
Change -0.98 ± 3.90 7.99 ± 4.26 0.127
NK cell activity E:T = 1.25:1 (%) 12.13 ± 1.62 12.91 ± 2.11 12.98 ± 1.63 19.51 ± 2.83 0.713 0.067
Change 2.18 ± 2.99 6.39 ± 3.12 0.335
NK cell activity E:T = 0.625:1 (%) 14.20 ± 2.96 11.80 ± 2.29** 14.50 ± 2.16 25.41 ± 4.13** 0.934 0.006
Change -2.66 ± 4.06 8.25 ± 5.01 0.097
Serum cytokines
IL-12 (pg/mL) 121.16 ± 42.81 54.83 ± 14.00 101.53 ± 36.56 70.26 ± 23.10 0.729 0.571
IFN-γ (pg/mL) 6.19 ± 1.22 6.73 ± 0.99 20.32 ± 12.80 18.35 ± 6.93 0.280 0.107
IL-1β (pg/mL) 2.10 ± 0.80 3.28 ± 2.23 1.64 ± 0.31 1.68 ± 0.30 0.590 0.482
IL-6 (pg/mL) 8.03 ± 1.69 10.17 ± 3.62 9.99 ± 1.96 7.13 ± 1.14 0.452 0.430
TNF-α (pg/mL) 18.32 ± 7.08 24.65 ± 12.83 19.81 ± 4.49 18.32 ± 3.83 0.860 0.639
Mean ± SE. 
1) P-values were derived from independent t-tests at baseline. 
2) P-values were derived from independent t-tests at the 2-week follow up. 
3) P-values were derived from independent t-tests for changed values. 
* P < 0.05 and ** P < 0.01 derived from paired t-test.
Table 4. Natural Killer (NK) cell activity and cytokine values in the control and test groups at baseline and at the 2-week follow up
Biochemical parameters
No significant differences were found in the concentrations 
of white blood cells, red blood cells, hemoglobin, platelets, serum 
albumin, prealbumin, transferrin, glucose, HDL cholesterol, LDL 
cholesterol, GOT, GPT, hs-CRP, and free fatty acids at baseline 
between the control and n3EN groups (Table 3).
Natural killer (NK) cell activity and cytokine concentrations
NK cell activities (%) were investigated based on effector: 
tumor (E:T) ratios of 10:1, 5:1, 2.5:1, 1:25:1 and 0.625:1. As outlined 
in Table 4 and Fig. 2, no significant differences were found in 
the NK cell activities measured at baseline between the two 
groups. The n3EN group’s NK cell activities at the 10:1, 5:1, 2.5:1 
and 0.625:1 E:T ratios were significantly higher than those of 
the control group at week 2 (P < 0.05) compared with the 
baseline values (Fig. 2). The n3EN group had larger increases 
in NK cell activity at ratios of E:T = 10:1, 5:1, and 0.625:1 than 
the control group (P < 0.05). No statistically significant differences 
were found in cytokine concentrations (IL-12, IFN-γ, IL-6, IL-1β 
and TNF-α) between the two groups (Table 4).
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(A)
(B)
Fig. 2. Increment of NK cell activities between the two groups at baseline
(0 week, ■) and follow up (2 week, □). Values are Mean ± SE. P-values were 
derived from independent t-tests.
DISCUSSION
Fatty acids can alter cell signaling, membrane properties, 
gene expression and the stimulation of bioactive regulators 
[25-27]. The lipid mediator system is important for mediating 
the inflammatory response [28]. Docosahexaenoic acid (DHA) 
and eicosapentaenoic acid (EPA) in fish oil and α-linolenic acid 
in plant oil are well known for promoting immune competence 
through promotion of anti-inflammatory eicosanoid synthesis 
[29]. Plant oils, especially flaxseed and canola oils, are good 
sources of n-3 fatty acids (C18:3). In a practical context, an 
enteral formula is generally used in large amounts on a daily 
basis for the long term. Therefore, a patient’s tolerance and 
preference and the stability of an enteral formula are considered 
important factors. The main reason that plant-derived n-3 fatty 
acid was incorporated into the test products used in our clinical 
trial rather than n-3 fatty acid from fish oil is because fish oil 
introduces stability problems and promotes an unacceptable 
taste and odor, and oxidation and hydrolysis quickly deteriorate 
the quality of fish oil [30]. Another issue is that fish oil’s functional 
substance may vary due to the variety of fish species and 
seasonal and geographical differences. When exposed to oxygen, 
fish oil can undergo oxidation and deterioration of its functional 
efficacy [31]. The stability and consistent quality of effective 
ingredients are crucial for enteral formulas given to patients. 
In addition, research showing that enteral formulas containing 
fish oil-derived n-3 PUFA are superior to plant-derived n-3 fatty 
acid formulas in hospitalized patients is lacking. Thus, we 
hypothesized that plant-derived n-3 oils may be desirable as 
fat components of an immune-enhancing enteral nutrition 
formula for rehabilitation patients. 
In this randomized, placebo-controlled study, the main 
findings indicated that the use of canola and flaxseed oils for 
enteral nutrition can be effective for activating the immune 
system by enhancing NK cell activities. Compared with the 
soybean oil formula (control) group, the plant-derived n-3 fatty 
acid-enriched formula group showed significantly greater 
increases in changes in NK cell activities at 10:1, 5:1, 2.5:1 and 
0.625:1 E:T ratios. This immune-modulating finding in our study 
shows that plant n-3 fatty acids had beneficial effects on NK 
cell activity, a marker of immune competence [28,32,33].
This result is in accordance with those of a previous reports 
in which n-3 fatty acids were shown to have immu-
nomodulatory effects in humans [7,34]. Generally, the evidence 
of an immune modulation effect of n-3 fatty acids is strongly 
supported by numerous studies. P.C. Calder summarized 
beneficial immune and inflammatory effects of n-3 fatty acids 
on monocytes in terms of phagocytosis, lymphocyte proliferation, 
cytokine production and human leucocyte antigen-D-related 
expression [34]. Recently, n-3 fatty acids have been reported 
to stimulate the immune system, inhibiting the cyclooxygenase 
(COX)-2 pathway of eicosanoid synthesis; therefore, a marked 
decrease occurs in pro-inflammatory prostaglandins such as 
PGE2, which favorably influences immune system modulation 
[35]. A recent report showing that NK cells have beneficial 
anti-infection and anti-inflammatory activities [36] supports the 
idea that therapeutic immune interventions applied to patients 
can stimulate the function of NK cells [37].
NK cells are a crucial factor in the innate immune system, 
representing 10% of the cells in the total peripheral blood 
mononuclear cell (PBMC) population of circulating human 
lymphocytes [38]. Additionally, previous studies have demon-
strated that cytokine production by PBMCs and several 
circulating cytokines also play vital roles in critically ill patients 
[18-20]. The stimulated levels of NK cell activity and blood 
cytokine concentrations are good indicators of host immunity 
because they reflect actual cell function, such as their ability 
to generate the important cytokines involved in immune 
defense [39]. Critically ill patients are known to exhibit hypore-
sponsive NK cell activity [40]. In this previous study, NK cell 
expression was significantly lower in septic subjects than that 
in non-septic subjects and a healthy control group. 
Decreases and increases in NK cell activity levels are related 
to the production of cytokines. A decrease in the expression 
level of NK cells results in altered production of cytokines. In 
a clinical prospective cohort study, the number of CD14+ 
monocytes yielding IL-12, TNF-α, and IL-6 was 40% to 70% lower 
in trauma patients than that in healthy control subjects [8]. In 
another study, critically ill pediatric patients with low stimulated 
TNF-α production were vulnerable to developing life-threatening 
complications [41,42].
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Although the canola and flaxseed oil formula group had 
higher NK cell activity levels in our study, no significant changes 
were observed in the five measured cytokines: IL-12, IFN-γ, IL-1
β, TNF-α and IL-6. Serum cytokine changes between the two 
groups and within the groups after two weeks of consuming 
each formula were not remarkable. These results regarding 
serum cytokines are inconsistent with the finding of Heyland 
DK et al. [11], which indicated that NK cells contribute to the 
immune reaction by presenting various potent immune- 
stimulating cytokines. On the other hand, our previously 
published study showed that despite NK cell activity upregula-
tion, no corresponding trends for serum cytokine activation 
were noted in critically ill patients [43]. In addition, Lee et al. 
[44] demonstrated serum cytokine and NK cell activity alterations 
according to age, and no positive or negative associations were 
found between NK cell activity and serum cytokines. These 
observations closely concurred with our findings. IL-6 and TNF-α 
have a short half-life [45], which may explain why we failed 
to find an association between hyper-NK cell activity and altered 
serum cytokine concentrations.
Furthermore, the wide discrepancy in cytokine levels in our 
study may be another factor underlying the lack of association 
found among immune markers, and serum cytokine homeostasis 
is unstable in hospitalized-rehabilitation patients [46]. In 
addition, Agarwal et al. [47] reiterated that the bioavailability 
and/or action of proinflammatory cytokines may depend on 
circulating cytokine receptors. Additionally, since cytokines are 
released in a paracrine manner, the levels may vary widely 
depending on when a subject’s blood sample is collected. 
Serum and plasma cytokine levels can be affected by receptor 
binding, temperature-induced degradation, urinary excretion, 
and cytokine breakdown within reacting cells [48]. Thus, these 
properties of cytokines may be another factor underlying the 
lack of association with NK cell activities and other immune 
parameters in our study. Additionally, this contradictory finding 
may be due to dissimilarities in the patients’ pathophysiological 
conditions. Our subjects were in the general inpatient ward, 
while most previous studies were conducted in critically ill 
patient care settings or in healthy subjects. Despite the small 
sample of sixty rehabilitation participants, this randomized 
placebo-controlled clinical study clearly showed that a 
combination of canola and flaxseed oils as a source of immune- 
modulating n-3 fatty acids in an enteral nutrition formula had 
beneficial effects without causing significant changes in serum 
cytokine levels, including IL-12, IFN-γ, IL-1β, IL-6 and TNF-α.
Several points should be considered when interpreting the 
present results. First, the small sample size of sixty enteral 
tube-fed patients warrants attention. The results should be 
confirmed by larger randomized controlled trials with sub-analyses 
by diagnosis, disease severity and age. Second, although the 
fatty acid profile of lipids (the fatty acid fraction) is less likely 
to be a practical parameter in our clinical setting because the 
fatty acid profile can be easily altered by total parenteral 
nutrition usage [49], we could not report the plasma fatty acid 
profiles of these patients because of limited blood (serum) 
volumes; therefore, NK cell activity, cytokine, and hematologic 
assessments were prioritized. Third, our results do not directly 
show that the increase in NK cell activity was correlated with 
cytokine changes as the circulating levels of measured cytokines 
may not reflect their true biological activity. Finally, as we 
focused on immune-specific parameters during two weeks of 
the patients’ hospitalizations, this study could not elucidate 
practical values such as the involuntary readmission rate, 
mortality, patients’ subjective tolerance or satisfaction scores, 
administrative costs, hospital stay durations, and follow-up 
clinical data after discharge regarding immune functions. Further 
investigation is required to evaluate the effects of plant-derived 
n-3 fatty acids on the immune system and clinical outcomes 
in larger long-term larger trials.
Despite these limitations, we demonstrated a greater increase 
in NK cell activity in the n3EN group. Immune-enhancing enteral 
nutrition enriched with canola and flaxseed oils yielded 
significant elevations in NK cell activities compared with the 
baseline levels, and a greater increase was observed in the n3EN 
group than that in the control group. In conclusion, this study 
shows the beneficial effects of plant-derived n-3 fatty acid 
supplementation in an enteral formula on NK cell activity.
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